Tom Frohlich

New Capabilities

As of June 2026: Leading JADE101 through Phase 2 with Phase 3 planned for 1H 2027

For decades, doctors had no drugs specifically approved for IgA nephropathy, a kidney disease that pushes up to half of patients toward kidney failure within ten years of diagnosis. Since December 2021, the FDA has approved five.

Updated Jun 1